Cadiz Inc

Cadiz Inc. maintains a highly leveraged capital structure with total liabilities of $130.5 million against total equity of $15.6 million, resulting in a debt-to-equity ratio of 5.48. The balance sheet includes $85.6 million in long-term debt and $16.5 million in cash and equivalents, leaving the company with negative net cash. Liquidity is assessed as high risk, supported by a current ratio of 1.88, though filings reference going-concern or substantial-doubt language. The company operates with a market capitalization of $258.1 million, trading at a price-to-book ratio of 26.08, which reflects significant market premium over its tangible book value despite negative earnings.

Profitability remains deeply negative, with Q1 2026 net income at -$8.6 million and operating income at -$6.8 million on revenue of $1.6 million. Return on equity stands at -2.19% and return on assets at -0.23%, indicating that the company is not yet generating returns on its invested capital. The valuation metrics, including an EV/EBITDA of -12.78 and EV/Revenue of 20.06, highlight the speculative nature of the investment, driven by future asset development potential rather than current earnings.

Revenue generation is minimal and concentrated in early-stage water resource activities. The company reports revenue of $1.6 million for Q1 2026, derived from its water and land resources and water treatment segments. The business model relies on developing a portfolio of 2.5 million acre-feet of permitted water supply and 1 million acre-feet of groundwater storage capacity. Geographic exposure is focused entirely on Southern California, specifically the Mojave Groundwater Bank and associated pipeline infrastructure, creating high concentration risk in a single regulatory and climatic jurisdiction.

Growth trajectory is characterized by pre-commercial development rather than organic revenue expansion. Historical data shows consistent net losses and minimal revenue generation, with the company relying on capital raises to fund operations. The Q1 2026 revenue of $1.6 million represents a small fraction of the total asset base, indicating that the company is in the infrastructure build-out phase. Future growth depends on the successful completion of water treatment facilities and pipeline construction, as well as securing long-term water purchase agreements.

Risk factors are elevated, with high liquidity risk and medium dilution risk flagged in the assessment. The company faces substantial doubt about its ability to continue as a going concern, as noted in recent filings. Key risks include the need for additional capital to fund development, regulatory hurdles in water rights and environmental compliance, and the potential for further equity dilution through direct offerings or convertible debt conversions. The high debt load and negative cash flow exacerbate these risks, requiring careful monitoring of covenant compliance and funding availability.

Recent events include an 8-K filing with high severity related to material agreements or changes, and a direct offering in March 2025 that raised capital through the issuance of common stock. The company also reported on the Lytton Agreement and progress in water filtration technology development. Analyst sentiment remains mixed, with a mean price target of $10.67 and a mean recommendation of 2.00 (Buy), suggesting that investors see long-term potential despite current financial challenges. The company continues to issue stock-based compensation to employees and consultants, further contributing to potential dilution.

Revenue grew at a 119.7% CAGR from FY2023 to FY2025, indicating strong top-line expansion momentum.

Free cash flow improved by 15.2% year-over-year in FY2025, suggesting better cash generation efficiency.

Capex to revenue ratio of 0.4644 ranks as best-in-class within the biotechnology cohort of 23 peers.

Operating income loss narrowed by 9.2% year-over-year in FY2025, showing slight improvement in operational performance.

Net income loss decreased by 8.8% year-over-year in FY2025, reflecting a marginal reduction in overall losses.

The company faces high liquidity risk, posing a significant threat to its ability to meet short-term obligations.

Debt-to-equity ratio of 5.48 places the company in the bottom quartile of its biotechnology peer group.

Return on equity of -2.1875 ranks in the bottom quartile among 34 biotechnology cohort peers.

Net margin of -2.09 is significantly below the cohort median of -0.15, indicating poor profitability.

The company carries a medium dilution risk, which could negatively impact existing shareholder value.

Revenue $1.6M; Operating income -$6.8M.

• ▍Revenue $1.6M
• ▍Operating income -$6.8M
• ▍Net margin -529.2%

Revenue $11.2M; Operating income -$18.2M.

• ▍Revenue $11.2M
• ▍Operating income -$18.2M
• ▍Net margin -217.2%

Revenue $7.1M; Operating income -$13.3M.

• ▍Revenue $7.1M
• ▍Operating income -$13.3M
• ▍Net margin -244.7%

Revenue $16.3M; Operating income -$25.6M.

• ▍Revenue $16.3M
• ▍Operating income -$25.6M
• ▍Net margin -209.3%

Revenue $9.6M; Operating income -$23.2M.

• ▍Revenue $9.6M
• ▍Operating income -$23.2M
• ▍Net margin -324.1%

Revenue $9.6M; Operating income -$23.2M.

• ▍Revenue $9.6M
• ▍Operating income -$23.2M
• ▍Net margin -324.1%

Revenue $2.0M; Operating income -$20.9M.

• ▍Revenue $2.0M
• ▍Operating income -$20.9M
• ▍Net margin -1579.4%

Revenue $2.0M; Operating income -$20.9M.

• ▍Revenue $2.0M
• ▍Operating income -$20.9M
• ▍Net margin -1579.4%